Kristin Brown, MD
Clinical Neurophysiology · Houston, TXNPI 1871858258
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.
Across 206 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$748
- Argenx US, Inc.$646
- Pfizer$476
- Teva Pharmaceuticals USA, Inc.$333
- CSL Behring$297
- Grifols USA, LLC$285
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,851100%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 42 | $748 |
| Argenx US, Inc. | 24 | $646 |
| Pfizer | 26 | $476 |
| Teva Pharmaceuticals USA, Inc. | 10 | $333 |
| CSL Behring | 13 | $297 |
| Grifols USA, LLC | 11 | $285 |
| AstraZeneca(2 entities) | 12 | $260 |
| UCB, Inc. | 9 | $257 |
| Lilly USA, LLC | 6 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $180 |
| Lundbeck LLC | 7 | $151 |
| Greenwich Biosciences, Inc. | 2 | $144 |
| Johnson & Johnson(2 entities) | 2 | $138 |
| Biogen | 6 | $104 |
| Abbott | 1 | $97 |
| Averitas Pharma Inc. | 3 | $68 |
| Microtransponder, Inc. | 1 | $65 |
| Hospira, Inc. | 3 | $64 |
| Acadia Pharmaceuticals Inc | 2 | $34 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Amgen | 2 | $32 |
| Alnylam Pharmaceuticals Inc. | 2 | $29 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $27 |
| Baxter Healthcare | 1 | $26 |
| Genentech USA, Inc. | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Amicus Therapeutics, Inc. | 1 | $13 |
| Catalyst Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$135
- Epidiolex$129
- INVEGA TRINZA$124
- INVEGA SUSTENNA$124
- Zilbrysq$108
- VYVGART$107
How this compares
$4,875 in reported general payments places this provider in the 65th percentile of 50 clinical neurophysiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvgartEfgartigimod Alfa-Fcab | 14 | $578,707 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 45 | $412,046 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 34 | $335,948 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 13 | $230,778 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 30 | $219,105 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 29 | $193,172 |
| VyeptiEptinezumab-Jjmr | 19 | $76,311 |
| Nurtec OdtRimegepant Sulfate | 36 | $50,098 |
| BotoxOnabotulinumtoxina | 34 | $44,204 |
| Emgality PenGalcanezumab-Gnlm | 44 | $34,590 |
| UbrelvyUbrogepant | 21 | $27,576 |
| Aimovig AutoinjectorErenumab-Aooe | 15 | $12,844 |
| NeuproRotigotine | 12 | $9,791 |
| Oxcarbazepine | 25 | $5,601 |
| Diclofenac Potassium | 16 | $4,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $297 | $747,99479 claims |
| Argenx US, Inc.Vyvgart | $646 | $578,70714 claims |
| PfizerOctagam, Nurtec Odt | $476 | $280,87649 claims |
| Grifols USA, LLCGamunex-C | $285 | $193,17229 claims |
| Lundbeck LLCVyepti | $151 | $76,31119 claims |
| AbbVieBotox, Ubrelvy | $748 | $71,78055 claims |
| UCB, Inc.Neupro | $257 | $9,79112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 50 clinical neurophysiology providers in Texas.
Other clinical neurophysiology in Houston
- Thy NguyenHouston$133K
- Nora Vanegas ArroyaveHouston$82K
- Samden LhatooHouston$66K
- Omotola HopeHouston$63K
- Hina DaveHouston$48K
- Monika UmmatHouston$36K
- Sudha TallavajhulaHouston$14K
- Victor LevinHouston$10K
- Shaun SmartHouston$9K
- Jay GavvalaHouston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.